@FierceMedDev: Bard settles vaginal mesh suit as thousands pend. ICYMI yesterday | Follow @FierceMedDev
@DamianFierce: Israel's InSightec is expanding into Canada with its surgery-free uterine fibroid treatment. News | Follow @DamianFierce
@MarkHFierce: We're launching a new diagnostics report in less than a week, and I'll be writing it. Sign up here | Follow @MarkHFierce
@MichaelGFierce: FDA clears Novo Nordisk's insulin injection pen for children. Item | Follow @MichaelGFierce
> InVivo Therapeutics ($NVIV) CEO Francis Reynolds is stepping down due to his medical condition, and Vivus ($VVUS) Chairman Michael Astrue is filling in while the company looks for a full-time chief. News
> Ivantis, developer of an eye stent to treat glaucoma, raised a $5 million Series B to help propel further clinical trial work. Item
> Dilon Diagnostics will distribute a number of Digirad's ($DRAD) nuclear imaging cameras. Item
> Molecular diagnostics company Atossa Genetics ($ATOS) will ring the Nasdaq closing bell to celebrate its Nov. 8, 2012 initial listing. Item
> eNeuras Therapeutics raised a small amount of new funding as it continues to develop a portable transcranial magnetic stimulation device to treat migraines. Item
> The entire amount of total knee replacements performed in the U.S. in 2009 saved $12 billion for patients and employers. Story
Biotech News
@FierceBiotech: Shire and Santaris extend their strategic alliance to discover, develop LNA-drugs in the rare disease field. Press release | Follow @FierceBiotech
@JohnCFierce: The latest on the Onyx buyout: Yes they are. No they aren't. Say what? Item | Follow @JohnCFierce
@EmilyMFierce: This week's career moves in biopharma. Chutes & Ladders | Follow @EmilyMFierce
> GlaxoSmithKline ponders future of Crohn's disease drug after PhIII flop. Report
> 3-D printing creates living tissue cells, holds promise for medical research. Story
> Vical restructures, chops 47 jobs after PhIII immunotherapy flop. Article
> Mystery doc cited for handing insider trial info to SAC trader. Report
Pharma News
@FiercePharma: Merck has the Zilmax PR right: Animal advocate Temple Grandin to consult on livestock drug's safety. More | Follow @FiercePharma
@EricPFierce: Regeneron takes a "byte" out of excess manufacturing capacity in Ireland. ICYMI yesterday | Follow @EricPFierce
@CarlyHFierce: Amid Purdue criticism, CVS cuts opioid access for 'risky' prescribers. ICYMI yesterday | Follow @CarlyHFierce
> Takeda presses on in emerging markets with Peru operation. Story
> SAC fund manager alleged to have not 1 but 2 docs feeding him insider info. More